Medicines for Europe commits at one year anniversary of HERA

9 December 2022
medicines-for-europe-big

Members of the trade group Medicines for Europe, which represents makers of biosimilar and generics drugs, are major suppliers of medicines for health crises. During the COVID pandemic, up to 90% of medicines needed in intensive care units were off patent medicines and our members have donated over 1,200 truckloads of medicines to help Ukraine.

The European Union Health Emergency Response Authority (HERA), established in February 2021 and fully launched in September last year following experience gathered during the pandemic, with the aim of preventing, detecting and rapidly responding to health emergencies.

For example, in June this year, the HERA ordered 110,000 doses of MVA-BN smallpox/monkeypox vaccine, to be made available to European Union member states, from Danish vaccine developer Bavarian Nordic (OMX: BAVA).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars